The resurgence of the norovirus GII.4 variant associated with sporadic gastroenteritis in the post-GII.17 period in South China, 2015 to 2017

Liang Xue 1, Weicheng Cai 1, Junshan Gao 1, Le Zhang 1, Ruimin Dong 2, Yonglai Li 2, Haoming Wu 1, Moutong Chen 1, Jumei Zhang 1, Juan Wang 3 and Qingping Wu 1*

Abstract

Background: Human norovirus is regarded as the leading cause of nonbacterial acute diarrhea in developing and developed countries. Among all genotypes, GII.4 has been the predominant genotype, but in East Asia, it was replaced by the GII.17 in 2014/2015. However, after the prevalence of new GII.17 variant in South China, a sharply increase in the number of norovirus infections associated with sporadic acute diarrhea was detected. In this study, we would investigate the prevalence and genetic diversity of noroviruses in the sporadic acute gastroenteritis cases in the post-GII.17 period in South China.

Methods: Norovirus was screened from 217 patients with sporadic acute gastroenteritis from August 2015 to October 2017 by reverse transcription-polymerase chain reaction. Then, two regions including the partial RNA polymerase and the capsid gene of positive samples were amplified and sequenced. Phylogenetic analyses were performed to determine norovirus genotypes. Complete VP1 sequences of GII.4 strains detected in this study were also amplified and subjected into evolutionary tracing analyses.

Results: A total of 43 (19.82%) norovirus samples were confirmed from 217 stool specimens, and it was found that GII.4 resurged as the new predominant variant, accounting for 76.74% (33/43) of positive samples. Only one local strain GZ2015-L550 was clustered with the contemporary GII.P16/GII.4–2012 recombinant variant, and other 32 local strains belonged to the clade with the GII.Pe/GII.4–2012 variant. Other genotypes including GII.17 (n = 4), GII.3 (n = 4), GII.8 (n = 1) and GI. 6 (n = 1) were also detected. Furthermore, all GII.4 strains were phylogenetic analyzed based on their capsid P2 subdomains. Combined with other reported 754 strains, the GII.4–2012 variant could be divided into two clades. Most GII.4 strains collected in 2016 and 2017 in this study (7/8) formed a new cluster A in Clade II with additional 103 contemporaneous strains. In addition, evolutionary tracing of the capsid P2 subdomain of this variant was also analyzed, and one specific amino acid substitutions (N373) was identified for Cluster A.

Conclusion: In summary, this study confirmed a norovirus infection peak in the post-GII.17 period in South China, which was caused by the resurgence of the GII.4 variant.

Keywords: Norovirus, Acute diarrhea, GII.4, Phylogenetic analyses, Recombination, Evolutionary tracing
Background
Norovirus (NoVs) is considered to be the main cause of non-bacterial acute gastroenteritis in developed and developing countries. This virus infects people of all ages and is responsible for almost one-fifth of all acute gastroenteritis cases worldwide [1]. This pathogen is responsible for almost half of all foodborne gastroenteritis outbreaks, and it is estimated that every year 200,000 children under 5 years old die from NoV associated gastroenteritis in developing countries [2, 3]. Huge medical economic and social losses caused by this virus have been estimated [4]. This virus can be transmitted by the fecal-oral pathway through contaminated environments, food, water, and person-to-person contact. Extensive NoV outbreaks are more prominent in semi-enclosed areas, including school, hospitals, nursing homes, cruise ships and holiday resorts [5]. NoV vaccine candidates have been tested in phase 1 and 2 clinical trials [6, 7], but there are still no licensed virus vaccines or effective medicine treatments against NoV infections as of this writing.

As a member of the family Caliciviridae, NoV is a single strand, positive-sense RNA virus. Its genome is approximately 7.5 kb to 7.7 kb in size and contains three open reading frames (ORFs) [8]. Given its high genetic diversity, NoVs could be classified into seven genogroups (G1 to GVII) based on the complete major capsid protein VP1 sequences [9, 10]. GI and GII NoVs are the genogroups primarily responsible for humans, and GIV could also infect humans. Genogroups could be further divided into more than 40 genotypes, and GI and GII include at least 9 and 22 genotypes, respectively [11]. Of all genotypes, GII.4 has been identified as the most predominant genotype for 70–80% of NoV outbreaks in most countries over the past 20 years [12]. The global pandemic spread of the GII.4 variant (US95/96) was first recognized in the mid-1990s. Then, after the emergence of GII.4 Farmington Hills 2002, new GII.4 variants appeared every 2 to 3 years and could spread globally within months [13]. In addition, a serial of non-GII.4 epidemic variants emerged recently have drawn extensive attention, especially the GII.17 Kawasaki 2014 in the winter of 2014/2015 [14–16].

In China, NoV gastroenteritis is also a public health concern, and this virus has been identified as one of the first two causes of acute diarrhea for more than a decade [17, 18]. A series of globally prevalent GII.4 variants have also been found in China, along with the GII.17 Kawasaki 2014 variant. However, a recent study showed that GII.17 did not completely replace GII.4, and a GII.P16/GII.4–2012 recombinant was detected as a new predominant variant [19, 20]. Recently, we detected a sharply increase in the number of NoV infections associated with sporadic acute diarrhea in South China. Increasing NoV infection activity is generally associated with the emergence of new epidemic variants. To give early warning of the next upcoming NoV season, we conducted a pilot study to characterize the prevalence and evolution patterns of NoV variants in the post-GI.I.17 period.

Methods
Fecal specimen collection
From August 2015 to October 2017, 217 fecal specimens were collected from patients suffering from acute diarrhea at the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, South China. All specimens were stored at −80 °C until further analyses.

Sample treatment, RNA extraction and NoV detection
A 10% (w/v) stool suspension was first prepared using phosphate-buffered saline (diethylpyrocarbonate-treated) and centrifuged at 10000 g for 1 min at 4 °C. Viral RNA was then extracted from 140 μL of the supernatant using a QiAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. One-step reverse transcription-polymerase chain reaction (RT-PCR) was employed for NoV detection using a one-step RT-PCR kit (TAKARA, Dalian, China) in this study. Genogroup-specific primers of G1SKF/G1SKR and G2SKF/G2SKR were used to screen for GI and GII NoV strains by amplifying the capsid N/S domain (region C in ORF2) [21]. Primers JV12Y and JV13I were also chosen to detect NoVs by amplifying a partial RNA-dependent RNA polymerase (RdRp) region (region A in ORF1) [22]. Besides, the primer set of NV2of2 and GV132 was used to amplify the full-length GII.4 NoV VP1 gene [23]. All tests were conducted in different rooms to avoid cross-contamination. In each run, RNase-Free distilled water served as a negative control, and a NoV-positive stool sample was used as a positive control.

Sequencing and phylogenetic analyses
After analyzed agarose gel electrophoresis, positive amplicons were purified from agarose gels using DNA extraction kits (Magentec, Guangzhou, China) following instructions, and then were subjected to direct sequencing using amplification primers. DNA sequencing was performed in the ABI Prism 3730XL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) using the BigDye® Terminator v3.1 Cycle Sequencing Kit, which was carried out by Majorbio Co., Ltd. (Shanghai, China). Nucleotide sequences data of detected NoV strains in this study were deposited in GenBank under accession numbers MH469166-MH469208.

All nucleotide sequences were first edited with the BioEdit® Sequence Alignment Editor software (v.7.0.1). NoV nucleotide sequences or derived amino acid sequences detected in this study with reference sequences of different genotypes were aligned using the ClustalX algorithm v1.83 with the default parameters [24]. For further phylogenetic analysis of local GII.4 NoV strains...
during the period from August 2015 to October 2017, a total of 754 reference GII.4 strains (including 751 GII.4–2012 strains, one GII.4–2009 strain, one GII.4–2006b strain, and one GII.4–2004) were also selected, and their information was listed in the Additional file 1 Table S2. We inferred maximum likelihood trees with Molecular Evolutionary Genetics Analysis (MEGA) v7.0 software [25], and best substitution models for the dataset were chosen based with the lowest Bayesian Information Criterion scores. Besides, neighbor–joining trees were also conducted with MEGA v7.0 software using the Kimura two-parameter model for nucleotide sequences. The reliability of the phylogenetic tree was assessed by bootstrap sampling of 1000 replicates. All nucleotide sequences were utilized to verify phylogenetic results [26].

Results
Prevalence of NoVs associated with sporadic acute diarrhea in South China
A total of 217 fecal specimens were collected from patients with acute diarrhea at the sentinel hospital from August 2015 to October 2017. Using the primer set targeting the capsid N/S domain, 43 samples (19.82%) were detected NoV positive, 42 of which were identified by G2SKF/G2SKR primers, and only one identified by G1SKF/G1SKR primers (Table 1).

Among all, 93 fecal samples were collected from female patients with the NoV positive rate of 21.51%, which was a little higher than that of male patients (23/124, 18.55%). Fifteen NoV positive samples were collected from children under 5 years old (n = 56) with the NoV positive rate of 26.79%, and three positive samples were collected from older children and teenagers between 5 and 18 years old (n = 11) with the positive rate of 27.27%, which were both higher than that of the adult group (28/161, 17.39%) (Table 2).

Genetic diversity of NoV strains during this surveillance
To identify the genotypes of the detected NoVs strains, nucleotide sequences of the capsid N/S domain (n = 43) amplified by G1SKF/G1SKR or G2SKF/G2SKR and the partial RdRp region (n = 43) amplified by JV12Y/JV13I were obtained for phylogenetic analyses. Only one strain, which collected from a seven-month-old baby boy in May 2016, belonged to GI genogroup (GI/6). Other 42 strains were clustered as GII genogroup, consisting of four genotypes (Fig. 1a). Most of these strains belonged to GII.4 (n = 33, 76.74%), and among them, partial RdRp regions from ten GII.4 strains were amplified and identified as GII.4b genotype. The positive rate of GII.4 NoVs reached 20.88% (2016) during the monitoring. Especially between August 2016 and February 2017, 24 GII.4 strains were detected with the positive rate of 46.15% (Fig. 2). In addition, four GII.17 positive samples were detected every year during the study period (August 2015, February and November 2016, January 2017), and two of them were also verified by the partial RdRp regions as GII.P17. Four GII.3 positive samples were also detected, which collected in August and November 2016. And one GII.P8/GII.8 strain was detected from a 27-year-old female patient in August 2017, which was the first one detected in mainland China.

Phylogenetic analyses and evolutionary tracing of GII.4–2012 strains based on the capsid P2 subdomain
For further understanding the cause of the sharply increase in the prevalence of NoV infections, local GII.4 strains (12 in this study, 6 in our previous study) were phylogenetically analyzed with other reference GII.4 strains (751 GII.4–2012 strains, one GII.4–2009 strain, one GII.4–2006b strain, and one GII.4–2004). Inferred ML trees based on their capsid P2 subdomains showed that all GII.4–2012 strains (n = 766) could be divided into two clades I (n = 115) and II (n = 651) (Fig. 3). Most local GII.4 strains collected in 2016 and 2017 in this study (7/8) formed a new cluster A in Clade II with other contemporaneous GII.4–2012 strains (n = 103). And one local strain G2Z2016-L550 was clustered with other GII.P16/GII.4–2012 strains (n = 48) as Cluster R in Clade I.

Based on multi-alignment results, evolutionary tracing of GII.4–2012 strains were subsequently performed, mainly focusing on five epitopes (A–E) and other three variable sites in the P2 subdomain (Fig. 4). The variable site was defined as being conserved in less than 95% of all strains. Only eight variable sites were identified for this variant, five of which located in the epitopes (A–D). For strains in Cluster R, their amino acid substitutions at these variable sites were consistent with those of other strains in Clade I. However, for strains in Cluster A, their amino acid substitutions at these variable sites were not completely consistent with those of other strains in Clade II, especially N373 only specific to Cluster A.

Discussion
After the emergence of GII.17 Kawasaki 2014 in South China, a sharply increase of NoV infections was found from August 2015 to October 2017. NoV positive rate was almost two times higher than those in our previous studies.
Findings in this study suggested that the resurgence of the GII.4 variant caused increased levels of NoV activity in the post GII.17 period. More interestingly, the GII.4 strains appeared in 2016 and 2017 had an obvious phylogenetic difference with previous ones. NoVs are regarded as the primary cause of acute viral gastroenteritis worldwide [3]. Despite its broad genetic diversity, GII.4 has been the predominant genotype in outbreaks and sporadic infections since its global pandemic [12]. The emergence of novel GII.4 epidemic variants has been continuously updated until the replacement of GII.4 Sydney 2012 by the novel GII.17 Kawasaki 2014 in 2014/2015 [15, 27]. It was of great significance for the pandemic of GII.17 Kawasaki 2014 as the first non-GII.4 epidemic variant, and it was even suggested whether GII.17 be the end of the GII.4 era [28]. However, epidemiological surveillance

| Patient profile | Number of samples collected | Number of positive sample (%) |
|-----------------|-----------------------------|-----------------------------|
| Gender          |                             |                             |
| Male            | 124                         | 23 (18.55%)                 |
| Female          | 93                          | 20 (21.51%)                 |
| Age             |                             |                             |
| <5 years old    | 56                          | 15 (26.79%)                 |
| 5–18 years old  | 11                          | 3 (27.27%)                  |
| >18 years old   | 150                         | 25 (16.67%)                 |

Table 2 Demography of NoV-positive patients detected in this study

Fig. 1 Phylogenetic trees of NoV strains based on the nucleotide sequences of (a) the partial capsid gene and (b) the partial RNA-dependent RNA polymerase gene. The dendrogram was constructed by the neighbor-joining method with the Kimura two-parameter model in MEGA v7.0 [25]. Numbers at the nodes indicate supporting bootstrap values (%) for 1000 resampled datasets; only values greater than 70% are shown. The scale bar represents the unit for the expected number of substitutions per site. Local NoV strains from this study are labelled by black triangles.
Fig. 2 Temporal distribution of norovirus positive strains detected during the period from August 2015 to October 2017, in South China. Norovirus genotypes are represented in this study by different colors in the legend (GII.4, red; GII.17, yellow; GII.3, blue; GII.8, green; GI.6, grey). And the numbers of samples tested per month were listed below the collecting time, which were in parentheses.

Fig. 3 Phylogenetic analysis of GII.4 NoV strains detected in South China during the period from August 2015 to October 2017, based on the nucleotide sequences of the capsid P2 subdomain. Phylogeny was reconstructed using the maximum-likelihood method implemented in MEGA v7.0 [25] with the TN93 + G + I model (best nucleotide substitution model for the dataset based with the lowest Bayesian Information Criterion scores). Numbers at the nodes indicate supporting bootstrap values (%) for 1000 resampled datasets, and bootstrap values of selected branches are shown (> 70%). The scale bar represents the unit for the expected number of substitutions per site. Local NoV strains from this study are labelled by red triangles (for strains in 2016 and 2017) and blue triangles (for strains in 2014 and 2015), respectively. Local NoV strains from previous studies are labelled by blue squares. Information of all reference sequences used for phylogenetic analysis in this figure was listed in the Additional file 1 Table S2.
data showed that GII.17 was detected less frequently after 2015 [27].

NoV epidemic and evolutionary characteristics after the emergence and prevalence of GII.17 is an important issue. Surveillance data from the NoroNet network suggested that no GII.4 drift variants emerged after 2012, and instead, the GII.42012 capsid seemed to persist through recombination. A novel GII.P16/GII.4 – 2012 variant has been detected in some countries since 2014, including China [19, 20]. In our study, only one strain GZ2016-L550 was detected as this recombinant genotype. Therefore, it was not considered to be the main reason for the increase in sporadic NoV infections in South China. Based on VP1 sequences, GIL.P16/GIL.4 – 2012 strains were phylogenetically separated from previously circulating GIL.4 – 2012 strains, but their antigenic domains in the capsid remains unchanged [29]. Besides, two other recombinants of GIL.Pe/GIL.4 – 2012 and GIL.P4 – 2009/GIL.4 – 2012 were also reported co-circulating with the GIL.P16/GIL.4 – 2012 [27, 30]. In addition to antigenic evolution, recombination is an important evolutionary pattern for GIL.4 genotype, and three recombination hot spots have been reported, including near the ORF1/ORF2 and ORF2/ORF3 overlaps, as well as within ORF2 [31]. However, the effect of GIL.4 recombination on its epidemic should be verified in the next work.

More importantly, the GIL.4 strains in the new Cluster A, which evolved by amino acid substitutions, were predicted as the cause of the sharply increase of NoV infections in this study. When compared with the previous GIL.4 strains, some obvious specific amino acid substitutions were identified (especially N373) [17]. It has been reported that under the pressure of herd immunity, the antigenicity of capsid protein VP1 gradually alters through variants selection [32, 33]. During the epidemic of the GIL.4 – 2012 variant, most of the variable amino acid sites (5/8) located in the previously reported epitopes (297, 372 in Epitope A, 333 in Epitope B, 340 in Epitope C, 393 in Epitope D). The change of one amino acid in the key epitope could cause the effect of virus immunogenicity, so the significance of these amino acid substitutions should be determined using antibody experiments in future work [13]. However, it should be noted that the bootstrap support on the root node of clade A is not more than 70 (only 48). Therefore, the novelty of N373 to clade A is supported by the inferred ML tree (Fig. 3), but N373 may not be specific to a single cluster.

We reported a new Cluster A consisted by recently detected GIL.4 – 2012 strains in the post-GIL.17 period, which was predicted to be responsible for the sharply increase in NoV prevalence in South China. This result was not completely consistent with the report based on surveillance data from the NoroNet network [27]. This inconsistency was mainly due to the different collection times of isolated strains. In addition, the limitation of our study was that our results were not from nationwide surveillance. However, newly emerged GIL.4 variants could spread globally within months after its emergence [13], and the similar situations for GIL.4 – 2012 and GIL.17 Kawasaki 2014 were also reported in China [34].

**Conclusion**

In conclusion, the resurgence of the GIL.4 variant in the post-GIL.17 period caused a sharply increase in the number of sporadic infection cases in South China. Most local GIL.4 strains evolved by amino acid substitutions and clustered into a new GIL.4 – 2012 Cluster A. Meanwhile, the recently reported GIL.4 – 2012 recombinant, which mainly caused outbreaks, was also rarely detected in this sporadic infection surveillance.
Additional file

Additional file 1: Table S1. Comparison of different studies about NoV prevalence associated with sporadic gastroenteritis in Guangzhou. Table S2. Information of norovirus reference sequences used in this study.

(DOCX 103 kb)

Abbreviations

GI: Genogroup I; GII: Genogroup II; MEGA: Molecular evolutionary genetic analysis; NoV: Norovirus; ORF: Open reading frames; RdRp: RNA-dependent RNA polymerase; RT-PCR: Reverse transcription polymerase chain reaction

Acknowledgements

We thank the staff of the Third Affiliated Hospital of Sun Yat-sen University for collecting the samples. And we also thank Dr. Zhenbo Xu and Dr. Yanru Ye thoroughly revising this manuscript.

Authors’ contributions

LX wrote the first manuscript draft and did the phylogenetic analysis. WCC, JWG, LZ, participated in the norovirus detection. HMW, JMW participated in the viral gene amplification. RMD, YLL did the epidemiological investigation. MTC, JW collected the data of clinical features and performed the statistical analysis. QPW, MTC, JMW, JH, HMW revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (31701717, 31872912), the National Key Research and Development Program of China (2017YFC1601200), Pearl River S&T Nova Program of Guangzhou (201610010020), GDAS Project of Science and Technology Development (2019GDASYL-0104008), and the Key Research and Development Program of Guangdong Province (2019B020200001). The funding body has no role in the design of the study; collection, analysis, and interpretation of data; and in writing the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article. The sequences of the NoV strains obtained in this study were deposited in the GenBank under the accession numbers MH469166-MH469208.

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee at the Third Affiliated Hospital of Sun Yat-sen University and the Institutional Review Board (IRB) at the Chinese CDC for the protection of human subjects. The project approval number is 2013(2)-76. After explaining the study objectives in their own local language, which could also help these diarrhea patients to detect norovirus infection free of charge, verbal consent was obtained from in their own local language, which could also help these diarrhea patients to detect norovirus infection free of charge, verbal consent was obtained from all participants or their guardian prior to sample collection. The procedures for verbal consent were approved by all ethical committees.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, No. 100, Xianlie Zhong Road, Guangzhou 510070, People’s Republic of China. 2Department of Cardiology, Laboratory Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, People’s Republic of China. 3College of Food Science, South China Agricultural University, Guangzhou 510642, People’s Republic of China.

Received: 2 February 2019 Accepted: 29 July 2019

References

1. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(8):725–30.
2. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14(8):1224–31.
3. Lopman BA, Steele D, Kirkwood CD, Parashar UD. The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Med. 2016; 13(4):e1001999.
4. Bartsch SM, Lopman BA, Ozaawa S, Hall AJ, Lee BY. Global economic burden of norovirus gastroenteritis. PLoS One. 2016;11(4):e0151219.
5. Moore MD, Goulter RM, Jaykus LA. Human norovirus as a foodborne pathogen: challenges and developments. Annu Rev Food Sci T. 2015;6:411–33.
6. Bernstein AJ, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinje J, Gregorics N, Frenck RW Jr, Moe CL, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015;211(6):870–8.
7. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Fereira J, Goodwin R, Botkowski A, Clemens R, Mendelmann PM. A novel intramuscular bivalent norovirus-like particle vaccine candidate—reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014; 210(1):1763–71.
8. Thome LG, Goodfellow KG. Norovirus gene expression and replication. J Gen Virol. 2014;95:278–91.
9. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology. 2006;346(2):313–23.
10. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol. 2015;53(3):2373–81.
11. de Graaf M, van Beek J, Koopmans MPG. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol. 2016;14(7):421–33.
12. Siebenga JJ, Vennema H, Zheng DP, Vinje J, Lee BE, Pang XL, Ho ECM, Lim W, Choudhake A, Broor S, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001–2007. J Infect Dis. 2009;200(5):802–12.
13. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 2008;5(2):269–90.
14. Xue L, Wu QP, Kou XX, Cai WC, Zhang JM, Guo WP. Genome characterization of a GII.6 norovirus strain identified in China. Infect Genet Evol. 2015;31:1107–10.
15. Xue L, Wu QP, Cai WC, Zhang JM, Guo WP. Molecular characterization of new emerging GII.17 norovirus strains from South China. Infect Genet Evol. 2016;40:1–7.
16. Matsuhashi Y, Ishikawa M, Shimizu T, Komane A, Kasuo S, Shinohara M, Nagasawa K, Kimura H, Ryo A, Okabe N, et al. Genetic analyses of GII.17 norovirus strains in diarrheal disease outbreaks from December 2014 to March 2015 in Japan reveal a novel polymerase sequence and amino acid substitutions in the capsid region. Eurosurveillance. 2015;20(26):2–7.
17. Xue L, Dong RM, Wu QP, Li YL, Cai WC, Kou XX, Zhang JM, Guo WP. Molecular epidemiology of noroviruses associated with sporadic gastroenteritis in Guangzhou, China, 2013–2015. Arch Virol. 2016;161(5):1377–84.
18. Xue L, Wu QP, Kou XX, Li YL, Cai WC, Zeng JM, Guo WP. Genetic analysis of a GII.6 norovirus strain identified in China. Infect Genet Evol. 2015;31:110–7.
19. Ruis C, Roy S, Brown JR, Allen DJ, Goldstein RA, Breuer J. The emerging GII.4. Norovirus in sporadic gastroenteritis in winter in Guangzhou, China. Foodborne Pathog Dis. 2015;12(10):888–95.
20. Ruis C, Roy S, Brown JR, Allen DJ, Goldstein RA, Breuer J. The emerging GII.4. Norovirus in sporadic gastroenteritis in winter in Guangzhou, China. Foodborne Pathog Dis. 2015;12(10):888–95.
21. Ruis C, Roy S, Brown JR, Allen DJ, Goldstein RA, Breuer J. The emerging GII.4. Norovirus in sporadic gastroenteritis in winter in Guangzhou, China. Foodborne Pathog Dis. 2015;12(10):888–95.
22. Sato K, Takeda N, Katayama K. Genogroup-specific PCR primers for detection of Norwalk-like virus. J Clin Microbiol. 2008;40:1–7.
23. Vennema H, de Bruin E, Koopmans M. Rational optimization of generic PCR primers for detection of Norwalk-like viruses. J Virol Methods. 2002;100:107–14.
24. Vennema H, de Bruin E, Koopmans M. Rational optimization of generic primers used for Norwalk-like virus detection by reverse transcriptase polymerase chain reaction. J Clin Virol. 2002;25(2):233–5.
23. Tu ET, Bull RA, Greening GE, Hewitt J, Lyon MJ, Marshall JA, McIver CJ, Rawlinson WD, White PA. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clin Infect Dis. 2008;46(3):413–20.

24. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25(24):4876–82.

25. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.

26. Kroneman A, Vennema H, Deforche K, von der Avoort H, Penaranda S, Oberste S, Vinje J, Koopmans M. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol. 2011;51(2):121–5.

27. van Beek J, de Graaf M, Al-Hello H, Allen DJ, Ambert-Balay K, Botteldoorn N, Brytting M, Buesa J, Cabrerizo M, Chan M, et al. Molecular surveillance of norovirus, 2005–16: an epidemiological analysis of data collected from the NoroNet network. Lancet Infect Dis. 2018;18:545–53.

28. de Graaf M, van Beek J, Vennema H, Podkolzin AT, Hewitt J, Bucardo F, Templeton K, Mans J, Nordgren J, Reuter G, et al. Emergence of a novel GII.17 norovirus - end of the GII.4 era? Eurosurveillance. 2015;20(26):8–15.

29. Cannon JL, Barclay L, Collins NR, Wikswo ME, Castro CJ, Magana LC, Gregoricus N, Marine RL, Chhabra P, Vinje J. Genetic and epidemiologic trends of norovirus outbreaks in the United States from 2013 to 2016 demonstrated emergence of novel GII.4 recombinant viruses. J Clin Microbiol. 2017;55(7):2208–21.

30. Bruggink L, Witlox K, Huang B, Warrilow D, Marshall J. GII.4 norovirus recombinant causes gastroenteritis epidemic in eastern Australia, winter 2017. J Med Virol. 2018;90:1168–71.

31. Eden J-S, Tanaka MM, Boni MF, Rawlinson WD, White PA. Recombination within the pandemic norovirus GII.4 lineage. J Virol. 2013;87(11):6270–82.

32. Siebenga JJ, Vennema H, Rencikens B, Bruijn E, van der Veer BD, Siezen RJ, Koopmans M. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol. 2007;81(18):9932–41.

33. Parra GI, Squires RB, Karangwa CK, Johnson JA, Lepore CJ, Sorosovtsev SV, Green KY. Static and evolving norovirus genotypes: implications for epidemiology and immunity. PLoS Pathog. 2017;13(1):e1006136.

34. Fu J, Ai J, Jin M, Jiang C, Zhang J, Shi C, Liu Q, Yuan Z, Qi X, Bao C, et al. Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015. Eurosurveillance. 2015;20(24):1–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.